MerLion secures first partner for lead drug finafloxacin
This article was originally published in Scrip
The private Singapore venture MerLion Pharmaceuticals has struck the first licensing deal for its lead therapeutic candidate, the fluoroquinolone antibiotic finafloxacin.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.